विकसित और हस्तांतरित प्रौद्योगिकियां



Technology Developed



Using receptor binding domain of spike protein, an ELISA has been developed to detect IgG antibodies against SARS-CoV-2. The sensitivity of developed IgG ELISA is 100% after 14 days from onset of symptoms or after 14 days from RT-PCR testing. Specificity is 98.6%.  

 Xcyton Diagnostics Limited 


A conventional PCR compatible-DNAzyme-based visual detection method for SARS-CoV-2 developed as an alternative to real-time PCR-based assay. 

Genei Labs


A panel of aptamers specific to SARS-CoV-2 spike protein developed.

Molbio Diagnostics


THSTI has developed a panel of Aptamers for diagnosing Coronavirus disease (hereinafter referred to as “COVID-19”) and associated know-how (as explained in Annexure I; referred in this Agreement as “Technology”), which can be used to develop testing kits to diagnose COVID-19 in humans (hereinafter referred to as “Products”).

Cambrain Bioworks LLP


THSTI has developed Integrative Expression Vector ‘pBD66N’ (“Vector”) and associated know-how, covered in Indian patent Application number 201911046890, which can be used as such as a genetic tool for therapeutic development and basic research (“Products”).

Bioheaven 360 Genotec Pvt. Ltd.